10:38 AM EDT, 07/08/2025 (MT Newswires) -- Maze Therapeutics' ( MAZE ) development strategy using genetic validation is seen as promising in terms of its target identification strategy and application to the nephrology and metabolic disease segments, Wedbush Securities said in a note Tuesday.

The firm said the Maze Compass platform using genetic variant analysis to name and validate potential targets is "impressive."

Wedbush added that competitor data is a source of external validation, which creates a degree of derisking related to the company's lead assets of MZE829 in APOL1 kidney disease and MZE728 in phenylketonuria.

"Combining multiple near-term catalysts with cash runway into [H2 of 2027], and we see favorable risk/reward for MAZE shares as the stock trades near a [roughly $500 million] valuation," the firm said.

Wedbush initiated coverage on the company with an outperform rating and $17 price target.

Shares of Maze Therapeutics ( MAZE ) were 5% in recent trading.

Price: 12.73, Change: +0.61, Percent Change: +5.03